For years, large pharmaceutical companies could rely on a familiar model: build a blockbuster drug, protect it through patents, maximise commercial value, and then use internal R&D to find the next growth engine. That model is becoming harder to sustain.
The industry is now facing a major patent cliff. Several high revenue drugs are expected to lose exclusivity over the next few years, exposing large pharma companies to generic and biosimilar competition. For companies that depend heavily on a few blockbuster products, this creates a serious portfolio problem. Future revenue gaps cannot be solved quickly through internal R&D alone.
That is why M&A in 2026 is not just about buying existing products. Big pharma is increasingly buying pipelines, platforms, and capabilities that can support the next decade of growth.
The central issue is timing.
Drug development takes years. Discovery, clinical trials, regulatory approval, manufacturing scale up, and commercial launch cannot be compressed easily. If a pharma company waits until revenue erosion begins, it is already too late.
This is why dealmaking is becoming more urgent. Large pharma companies are using acquisitions and partnerships to bring in assets that can strengthen their future portfolios before the revenue gap becomes visible.
In the past, a buyer may have preferred a marketed product with clear sales and lower scientific risk. Today, the more attractive target may be a biotech company with a promising Phase I, Phase II, or Phase III asset in a high growth therapeutic area.
The logic is simple: big pharma is not just buying revenue. It is buying time.
A single product can help fill a revenue gap. A strong pipeline can reshape a company’s future growth profile.
That distinction matters because patent cliffs rarely create one isolated problem. They create portfolio level pressure. A company may need multiple future drugs to replace the decline from one or two major blockbusters.
This is why pipeline led deals are becoming more attractive. They give acquirers several shots on goal. Even if one asset fails, the broader platform or therapeutic focus may still create value.
This is also why pharma companies are looking beyond traditional commercial assets. They are increasingly interested in areas such as obesity, oncology, immunology, antibody drug conjugates, radiopharma, and advanced delivery technologies.
In these areas, the strategic value is not always limited to one drug. It can sit in the science, the modality, the manufacturing process, or the development platform.
Several recent deals reflect this new M&A logic.
GSK’s acquisition of RAPT Therapeutics was focused on an experimental food allergy drug, not a mature commercial asset. The deal gives GSK another potential future growth driver as it prepares for patent pressure in other parts of its portfolio.
GSK also agreed to acquire 35Pharma, adding an experimental pulmonary hypertension drug to its respiratory pipeline. Again, the point was not immediate revenue. The point was future portfolio strength.
Merck’s acquisition of Terns Pharmaceuticals follows a similar pattern. With Keytruda facing future patent pressure, Merck needs to deepen its oncology pipeline and reduce dependence on a single major franchise.
Gilead’s move to acquire Tubulis also reflects the growing importance of platform based M&A. Tubulis gives Gilead exposure to antibody drug conjugates, one of the most important areas in oncology innovation.
These deals are different in size and therapeutic focus, but the underlying logic is similar. Large pharma companies are using M&A to secure future growth before existing revenue streams come under pressure.
Another important shift is the rise of China as a source of pharma innovation.
Large pharma companies are increasingly using licensing deals and partnerships to access Chinese drug candidates. This shows that China is no longer viewed only as a manufacturing base or commercial market. It is becoming an important source of differentiated science.
For big pharma, this creates another route to pipeline expansion. Instead of acquiring an entire company, a buyer can license a promising asset, share development risk, and preserve optionality.
This is especially useful when assets are still early stage. Full acquisitions provide control, but partnerships can provide access without concentrating all the risk upfront.
The bigger story is that pharma M&A is becoming more strategic and more capability led.
Buyers are not only asking: how much revenue can this asset generate?
They are asking:
Can this target strengthen a future therapeutic franchise?
Can this platform produce more than one drug?
Can this capability reduce development or manufacturing bottlenecks?
Can this deal help us compete in a future profit pool?
That is a very different M&A lens. It moves pharma dealmaking away from simple product replacement and toward long term portfolio building.
Pharma M&A in 2026 is not just a rebound in deal activity. It is a response to a structural problem.
The patent cliff is forcing large pharma companies to act before revenue pressure becomes unavoidable. Internal R&D remains important, but it may not be fast enough on its own. As a result, companies are buying clinical pipelines, scientific platforms, manufacturing capabilities, and innovation access.
The winners will not simply be the companies that spend the most. They will be the companies that know which therapeutic areas they want to dominate, which capabilities they need to control, and which scientific bets are worth making early.
This is a personal blog written in an individual capacity. The views expressed are my own and do not represent those of any employer, client, or affiliated organization. All content is based on publicly available information and is intended for educational purposes only. No confidential or client specific information is used. Nothing here constitutes investment, legal, or professional advice.
